Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 308-314

  Yunoki, Kei ^a   Naruko, Takahiko ^a   Inaba, Mayumi ^b   Inoue, Takeshi ^a   Nakagawa, Masashi ^b   Sugioka, Kenichi ^b   Ohsawa, Masahiko ^b   Iwasa, Yoko ^b   Komatsu, Ryushi ^a   Itoh, Akira ^a   Haze, Kazuo ^a   Yoshiyama, Minoru ^b   Becker, Anton E ^c   Ueda, Makiko ^b  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angina; Myeloperoxidase; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ANGINA; MYELOPEROXIDASE; OXIDATIVE STRESS; PARAOXONASE;

AGED; ANGINA, STABLE; ANGINA, UNSTABLE; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; PEROXIDASE; POLYMORPHISM, GENETIC; SEX FACTORS;

EID: 84888094525     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.037     Document Type: Article

References (45)

1. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. JAm Coll Cardiol 2006, 47:C19-C31.
2. Nicholls S.J., Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
3. Podrez E.A., Schmitt D., Hoff H.F., Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form invitro. JClin Invest 1999, 103:1547-1560.
4. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002, 106:2894-2900.
5. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. NEngl J Med 2003, 349:1595-1604.
6. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
7. Yunoki K., Naruko T., Komatsu R., et al. Relation of elevated levels of plasma myeloperoxidase to impaired myocardial microcirculation after reperfusion in patients with acute myocardial infarction. Am J Cardiol 2010, 105:922-929.
8. Naruko T., Furukawa A., Yunoki K., et al. Increased expression and plasma levels of myeloperoxidase are closely related to the presence of angiographically-detected complex lesion morphology in unstable angina. Heart 2010, 96:1716-1722.
9. Yunoki K., Naruko T., Sugioka K., et al. Erythrocyte-rich thrombus aspirated from patients with ST-elevation myocardial infarction: association with oxidative stress and its impact on myocardial reperfusion. Eur Heart J 2012, 33:1480-1490.
10. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
11. Granér M., James R.W., Kahri J., Nieminen M.S., Syvänne M., Taskinen M.R. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. JAm Coll Cardiol 2006, 47:2429-2435.
12. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003, 107:2775-2779.
13. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. JClin Invest 2004, 114:529-541.
14. Rosenblat M., Vaya J., Shih D., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005, 179:69-77.
15. Austen W.G., Edwards J.E., Frye R.L., et al. Areporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association. Circulation 1975, 51:5-40.
16. Hamm C.W., Braunwald E. Aclassification of unstable angina revisited. Circulation 2000, 102:118-122.
17. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
18. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
19. Hata Y., Mabuchi H., Saito Y., et al. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. JAtheroscler Thromb 2002, 9:1-27.
20. Kujiraoka T., Oka T., Ishihara M., et al. Asandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. JLipid Res 2000, 41:1358-1363.
21. Eckerson H.W., Romson J., Wyte C., La Du B.N. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983, 35:214-227.
22. Nakanishi M., Takanami Y., Maruyama T., et al. The ratio of serum paraoxonase/arylesterase activity using an improved assay for arylesterase activity to discriminate PON1(R192) from PON1(Q192). JAtheroscler Thromb 2003, 10:337-342.
23. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3:73-76.
24. Maugeri N., Rovere-Querini P., Evangelista V., et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS One 2012, 7:e39484.
25. Buffon A., Biasucci L.M., D'Onofrio G., Liuzzo G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. NEngl J Med 2002, 347:5-12.
26. Adkins S., Gan K.N., Mody M., La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52:598-608.
27. Gluba A., Pietrucha T., Banach M., Piotrowski G., Rysz J. The role of polymorphisms within paraoxonase (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology 2010, 61:157-165.
28. Mackness B., Turkie W., Mackness M. Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease. Arch Med Sci 2013, 9:8-13.
29. Wadham C., Albanese N., Roberts J., et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004, 109:2116-2122.
30. Soro-Paavonen A., Westerbacka J., Ehnholm C., Taskinen M.R. Metabolic syndrome aggravates the increased endothelial activation and lowgrade inflammation in subjects with familial low HDL. Ann Med 2006, 38:229-238.
31. lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:1832-1841.
32. Norata G.D., Pirillo A., Ammirati E., Catapano A.L. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis 2012, 220:11-21.
33. Otocka-Kmiecik A., Mikhailidis D.P., Nicholls S.J., Davidson M., Rysz J., Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res 2012, 51:314-324.
34. Jornayvaz F.R., Brulhart-Meynet M.C., James R.W. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009, 19:613-619.
35. Barylski M., Mikhailidis D.P., Ciebiada M., Rysz J., Banach M. Gender differences in the treatment of ischemic heart disease. Curr Pharm Des 2011, 17:1059-1069.
36. Trevisan M., Browne R., Ram M., et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol 2001, 154:348-356.
37. Sánchez-Rodríguez M.A., Zacarías-Flores M., Arronte-Rosales A., Correa-Muñoz E., Mendoza-Núñez V.M. Menopause as risk factor for oxidative stress. Menopause 2012, 19:361-367.
38. Asada Y., Komura S., Ohishi N., et al. Effect of ovariectomy on serum lipid peroxide levels in women. JClin Biochem Nutr 1990, 8:247-252.
39. Vassalle C., Sciarrino R., Bianchi S., Battaglia D., Mercuri A., Maffei S. Sex-related differences in association of oxidative stress status with coronary artery disease. Fertil Steril 2012, 97:414-419.
40. Hermenegildo C., García-Martínez M.C., Valldecabres C., Tarín J.J., Cano A. Transdermal estradiol reduces plasma myeloperoxidase levels without affecting the LDL resistance to oxidation or the LDL particle size. Menopause 2002, 9:102-109.
41. Sutherland W.H., Manning P.J., de Jong S.A., Allum A.R., Jones S.D., Williams S.M. Hormone-replacement therapy increases serum paraoxonase arylesterase activity in diabetic postmenopausal women. Metabolism 2001, 50:319-324.
42. Zhang R., Shen Z., Nauseef W.M., Hazen S.L. Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood 2002, 99:1802-1810.
43. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 2004, 24:1143-1146.
44. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:473-480.
45. Regieli J.J., Jukema J.W., Doevendans P.A., et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. JAm Coll Cardiol 2009, 54:1238-1245.